National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
2,051 of 2,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
3,257 total, page 66 of 66
The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors
NCT00001189
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation
NCT01468883
Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers
NCT00001164
The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
NCT00005660
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
NCT00001150
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
NCT00000652
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Cancer Institute (NCI): open-pipeline peers nationwide
Peers matched on 3,257 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Cancer Institute (NCI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3,257 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- M.D. Anderson Cancer Center · 2,692 trials · 20% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this National Cancer Institute (NCI) page
3,257 registered trials is a research-attention snapshot, not an endorsement of National Cancer Institute (NCI) or any single study.
- 326 of National Cancer Institute (NCI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Malignant Solid Neoplasm is the condition National Cancer Institute (NCI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Cancer Institute (NCI) pipeline card: 3,257 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.